~~<i id='6A5C313182'><strike id='6A5C313182'><tt id='6A5C313182'><pre id='6A5C313182'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

knowledge

author：hotspot 2025-09-28 04:25:41 - browse：252

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Donald Trump's relentless attacks on special counsel Jack Smith

hotspot

explore

hotspot

focus

explore

PeopleacrosstheU.S.willbeabletowatchMonday'ssolareclipse—butcanwatchingitwithoutanyeyeprotectionhurt

WSS

Disclosing genetic information: not as worrisome as once feared

#NeedHerScience: shining a light on gender disparities in medicine

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Readout Newsletter: Merck, J&J, and long Covid

How digital therapeutics firms are pivoting after Pear's bankruptcy

Wikipedia

knowledge

hotspot

Drug repurposing or repositioning? The language matters

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Cancer drug shortages should be causing more outrage

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

In age of alternative facts, a scholarly course on calling out crap

Cloning humans is technically possible. It's curious no one has tried

ChatGPT in medicine: STAT answers readers' burning questions

The story of mRNA: From a loose idea to a tool that may help curb Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The surgeon had a dilemma only a Nazi medical text could resolve

explore

New guidelines on severe brain injury complicate already difficult decisions

Paxlovid study fails to answer questions over benefit for broader groups

Colonoscopy at 40? Study finds a possible benefit

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Donald Trump's relentless attacks on special counsel Jack Smith

The story of mRNA: From a loose idea to a tool that may help curb Covid

hotspot

focus

focus

explore